-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target

Benzinga·05/09/2025 10:48:36
Listen to the news
Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $65 price target.